Observational studyBMJ open2025
The Effect of Multimorbidity and Anticoagulation Use in Patients with Atrial Fibrillation on The One-Year Outcome: Analysis from Jordan Atrial Fibrillation (JoFIB) Study - A Prospective Cohort Study.
Observational study in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03917992 (The Baseline Features and CHA2DS2 VASc /HAS BLED Scores of Jordanian Patients With Atrial Fibrillation and the One Year Outcome), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Baseline Features and CHA2DS2 VASc /HAS BLED Scores of Jordanian Patients With Atrial Fibrillation and the One Year Outcome
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePatients with atrial fibrillation (AF) frequently have multiple comorbidities that increase the risk of hospitalisation and contribute to higher mortality. However, studies examining the prevalence of comorbidities among Middle Eastern patients with AF and their impact on clinical outcomes are scarce. This study aimed to assess the impact of comorbidities in a Middle Eastern population with AF treated with contemporary anticoagulation.
designProspective observational cohort study.
settingPatients from 20 hospitals and 30 outpatient cardiology clinics across Jordan were enrolled from May 2019 through October 2020.
participants2020 consecutive patients were enrolled. 117 of them were lost to follow-up, and 1903 had available data for analysis. Of the total, 1096 (54.3%) patients were women, and 924 (45.7%) were men. Eligible patients were 18 years of age or above, had a confirmed AF diagnosis and provided informed consent. PRIMARY AND SECONDARY OUTCOMES: We are examining the outcomes of patients with AF, comparing those who have multimorbidities versus oligomorbidities. The primary outcomes were AF-related complications occurring within 1-year follow-up: major bleeding, non-major bleeding, stroke/cerebrovascular accidents, systemic emboli and acute coronary syndrome. Secondary outcomes included causes of death among deceased patients.
resultsAmong the cohort, 1160 (57.4%) had two or less comorbidities (oligomorbidity group) and 860 (42.6%) had three or more comorbidities (multimorbidity group). Compared with the oligomorbidity group, the multimorbidity group had significantly higher rates of hypertension (97.9% vs 57.2%), diabetes mellitus type II (92.4% vs 7.3%), cardiovascular disease (100% vs 79.6%), chronic kidney disease (18.4% vs 1.8%) and chronic lung disease (7% vs 1%, p<0.001 for all comparisons). Over the 1-year follow-up, the multimorbidity group experienced higher rates of hospitalisation (24% vs 16.9%, p<0.001), all-cause death (21.4% vs 9.5%, p<0.001) and cardiovascular death (11.8% vs 4.7%, p=0.002) than the oligomorbidity group. All-cause mortality in the multimorbid group was mostly related to hypertension with an OR of 5.5 (95% CI 2.07 to 14.73), history of stroke (OR 2.7, 95% CI1.85-4.03) and heart failure (OR 2.3, 95% CI 1.64 to 3.33). However, the use of warfarin (OR 0.6, 95% CI 0.38 to 0.82) and novel oral anticoagulants (OR 0.7, 95% CI 0.46 to 0.91) had protective effects from all-cause mortality.
conclusionMiddle Eastern patients with AF appear to exhibit a high burden of comorbidities. The results suggest the more comorbidities in these patients, the higher the rates of hospitalisation and death. TRIAL REGISTRATION NUMBER: NCT03917992.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.